PTGDS2, aa1-199, Recombinant, Human (Hematopoietic Prostaglandin D Synthase, H-PGDS, GST Class-sigma

Prostaglandin D Synthase (PGDS) catalyzes the conversion of prostaglandin (PG) H2 to PGD2, which is a major prostanoid produced in a variety of tissues. Two types of PGDS have been isolated, the glutathione-dependent hematopoietic PGDS (HPGDS) and the glutathione-independent lipocalin-type PGDS (1). HPGDS is a cytosolic enzyme that is expressed in mast cells and antigen presenting cells (2, 3). It is the only mammalian member of the class Sigma glutathione S-transferase, showing a broad specificity towards standard transferase substrates (4). The PGD2 produced by HPGDS is involved in many physiological processes such as maintaining body temperature, promotion of sleep, inhibition of platelet aggregation and bronchoconstriction (5). It also functions in immune response and acts as a mediator in allergy and inflammation (6). HPGDS-specific inhibitors may be therapeutically useful anti-allergic and anti-inflammatory drugs. Source: Recombinant corresponding to aa1-199 from human Hematopoietic Prostaglandin D Synthase, fused with 6-His tag at C-terminal, expressed in E. coli. Molecular Weight: ~64kD, Endotoxin Level: <1EU/1ug (LAL), Biological Activity: Measured by its ability to hydrolyze the donor substrate GDP-fucose. The specific activity is >0.75pmoles/min/ug, as measured under the described conditions. Storage and Stability: Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for at least 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.